ProstaDOT: Diffuse optical tomography for prostate cancer detection

Unmet Medical Need: Prostate cancer is the leading cause of death among men. However, with current detection methods, it is difficult to scale cancer and correctly identify its location, leading to under or over-treatment and potentially unnecessary surgery, causing side effects such as impotence and incontinence. 

Envisioned Healthcare Product: The ProstaDOT technology utilizes diffuse optical tomography to accurately diagnose and risk stratify to appropriately select men for treatment. A combination of ultrasound and optical imaging ensures accurate assessments of prostate cancer aggressiveness and risk of recurrence. The technology can easily be incorporated into existing commercial probes and ultrasound devices, and has great potential to lead to improved health outcomes for men due to improved detection and risk stratification of prostate cancer. 

Stage of Development: Hypothesis testing, proof of concept, Ongoing Clinical Trial


January 2016 Article

Collaborative Research Team: Hyun Keol Kim, PhD and Emerson Lim, MD

Funding Cycle: 2016-2017